PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search > PAD Profile : Sildenafil (Erectile Dysfunction) - Erectile dysfunction

PAD Profile : Sildenafil (Erectile Dysfunction) - Erectile dysfunction

Keywords :
Phosphodiesterase type 5 inhibitors, ED, Impotence, PDE5, PDE-5
Brand Names Include :
Viagra, Nipatra

Traffic Light Status

Status 1 of 1.

Status :
Green
Important Preferred
Formulations :
  • Tablets
Important Information :
1st line option
Trust Alignment :
Primary Care
ASPH
RSCH
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
05 September 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

For patients who meet SLS criteria 

  •  Sildenafil (generic): It is reasonable to prescribe up to 3 tablets per week  OR
  • Tadalafil (generic) It is reasonable to prescribe up to 1 tablet  per week as tadalafil is longer acting than sildenafil

Sildenafil (generic) or Tadalafil (generic) are considered  as GREEN on the traffic light system

For patients who do NOT meet SLS criteria 

  • Generic sildenafil (generic) is currently approved for prescribing for those patients
  • Sildenafil (generic) is considered  as GREEN on the traffic light system

Combination treatments (oral & non oral)
These treatments should not be used in combination with other treatments for erectile dysfunction due to the limited evidence available to support their use. See here for further information https://surreyccg.res-systems.net/pad/Search/DrugConditionProfile/6165

PLEASE NOTE: The branded product, Viagra, is considered BLACK.

Associated BNF Codes

07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.05. Drugs for erectile dysfunction
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More